ICU•SeaStar Medical reported Q3 revenue of $635,000, above the $450,500 consensus estimate, and a net loss of $4.53 million. The company expects enrollment in its NEUTRALIZE-AKI trial to be completed by mid-year 2027.
SeaStar Medical said Q3 net revenue rose year over year as adoption of its QUELIMMUNE therapy expanded for pediatric sepsis-associated acute kidney injury. The company reported a net loss of $4.53 million, with higher research and development expenses driven by clinical research for the NEUTRALIZE-AKI trial and SCD development.
SeaStar Medical expects enrollment in the NEUTRALIZE-AKI trial to be completed by mid-year 2027. The company said fulfillment of FDA post-approval SAVE Registry requirements may increase hospital access to QUELIMMUNE.
